Walder Wyss advised SixPeaks Bio AG while Lenz & Staehelin acted as Swiss counsel to AstraZeneca. SixPeaks Bio AG has secured USD30 million in Series A...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Axalta Coating Systems on this transaction. Axalta Coating Systems Group (NYSE: AXTA) acquired André Koch AG, an established provider of car repair and...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Boehringer Ingelheim in the transaction. Boehringer Ingelheim announced the acquisition of privately-held T3 Pharmaceuticals AG, a clinical stage Swiss biotech company, for an...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised the investors while VISCHER acted as legal advisor to Nouscom in the transaction. Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised CONVOTIS on all aspects of Swiss law on the transaction. CONVOTIS strengthens its position in Switzerland with the acquisition of acdalis AG, a...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on this transaction. ierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer...
You must be a Standard 1 Year member to access this content.
Walder Wyss advises Alentis Therapeutics on the financing. Alentis Therapeutics has announced $105 million in Series C financing. The funding round was led by Jeito Capital...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised BC Platforms on the deal. BC Platforms announced a USD 20m growth financing led by Jolt Capital. BC Platforms is a global leader in...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on the deal. Versant Ventures announced the debut of Vector BioPharma, a biopharmaceutical company developing a precision gene delivery platform that...
You must be a Standard 1 Year member to access this content.
MLLStart! advised Clinical Research Ventures. Walder Wyss advises BioVersys. BioVersys AG, a privately-held clinical-stage, multi-asset Swiss pharmaceutical company focusing on research and development of therapies for...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Engimmune Therapeutics on the deal. Vischer advised the investors Pureos Bio-ventures and Novo Holdings. Engimmune Therapeutics completed a CHF 15.5m seed financing round co-led...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Versant Ventures on the deal. VISCHER advised Cimeo Therapeutics. Versant Ventures announced the debut of Cimeio Therapeutics, a biotechnology company developing a novel...
You must be a Standard 1 Year member to access this content.
